吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GILD 吉利德科学

盘后交易 12-11 17:23:25 EST

80.09

+1.07

+1.35%

盘后80.17

+0.08+0.10%

17:10 EST

最高80.84	最低79.46	成交量818.85万
今开79.63	昨收79.02	日振幅1.75%
总市值997.95亿	流通市值996.68亿	总股本12.46亿
成交额6.55亿	换手率0.66%	流通股本12.44亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"GILD","market":"US","secType":"STK","nameCN":"吉利德科学","latestPrice":80.09,"timestamp":1702328400000,"preClose":79.02,"halted":0,"volume":8188494,"hourTrading":{"tag":"盘后","latestPrice":80.17,"preClose":80.09,"latestTime":"17:10 EST","volume":329104,"amount":26357950.549536,"timestamp":1702332655020},"delay":0,"floatShares":1244446587,"shares":1246041895,"eps":4.669393,"marketStatus":"盘后交易","marketStatusCode":4,"change":1.07,"latestTime":"12-11 17:23:25 EST","open":79.63,"high":80.84,"low":79.46,"amount":655249267.48062,"amplitude":0.017464,"askPrice":80.16,"askSize":300,"bidPrice":80.1,"bidSize":116,"shortable":3,"etf":0,"ttmEps":4.669393,"exchange":"NASDAQ","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1702342800000},"adr":0,"listingDate":696056400000,"adjPreClose":79.02,"adrRate":0,"dividendRate":0.037208,"preHourTrading":{"tag":"盘前","latestPrice":79.63,"preClose":79.02,"latestTime":"09:29 EST","volume":7034,"amount":558816.20034,"timestamp":1702304999999},"postHourTrading":{"tag":"盘后","latestPrice":80.17,"preClose":80.09,"latestTime":"17:10 EST","volume":329104,"amount":26357950.549536,"timestamp":1702332655020},"volumeRatio":1.1574},"requestUrl":"/m/hq/s/GILD","defaultTab":"news","newsList":[{"id":"2390864190","title":"吉利德科学上涨1.22%，报79.0美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2390864190","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2390864190?lang=zh_cn&edition=full","pubTime":"2023-12-09 02:05","pubTimestamp":1702058715,"startTime":"0","endTime":"0","summary":"12月9日，吉利德科学(GILD)盘中上涨1.22%，截至02:05，报79.0美元/股，成交2.05亿美元。财务数据显示，截至2023年09月30日，吉利德科学收入总额200.02亿美元，同比增长0.55%；归母净利润42.36亿美元，同比增长43.5%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2023/12/09020538716383.shtml","is_publish_highlight":false},{"id":"2389247700","title":"吉利德科学下跌1.21%，报78.4美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2389247700","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2389247700?lang=zh_cn&edition=full","pubTime":"2023-12-07 23:00","pubTimestamp":1701961237,"startTime":"0","endTime":"0","summary":"12月7日，吉利德科学(GILD)盘中下跌1.21%，截至23:00，报78.4美元/股，成交1.17亿美元。财务数据显示，截至2023年09月30日，吉利德科学收入总额200.02亿美元，同比增长0.55%；归母净利润42.36亿美元，同比增长43.5%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2023/12/07230038703227.shtml","is_publish_highlight":false},{"id":"2389047273","title":"更新版 1-默克公司的肺癌药物组合未能达到试验目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2389047273","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2389047273?lang=zh_cn&edition=full","pubTime":"2023-12-07 19:37","pubTimestamp":1701949036,"startTime":"0","endTime":"0","summary":"    路透12月7日 - 默克公司  周四表示，在一项中期研究中，其与Keytruda联合治疗一种肺癌的实验性疗法没有达到主要目标。默克公司的实验性药物Vibostolimab与其大片药物Keytruda联用，未能有意义地延缓转移性非小细胞肺癌患者的疾病进展和改善总生存期。默克 公司的挫折标志着 继罗氏公司的疗法在去年的第二次试验中 ，未能延缓一种肺癌的进展之后，正在探索抗TIGIT 疗法的半打以上公司遭受的第二次重大打击。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false},{"id":"2388231067","title":"联合吉利德科学，金域医学助力17个城市开展艾滋病免费筛查","url":"https://stock-news.laohu8.com/highlight/detail?id=2388231067","media":"时代周报","top":-1,"share":"https://www.laohu8.com/m/news/2388231067?lang=zh_cn&edition=full","pubTime":"2023-12-01 20:20","pubTimestamp":1701433243,"startTime":"0","endTime":"0","summary":"活动将持续一个月，覆盖成都、重庆、南宁、广州等17个城市，计划为数万名群众提供艾滋病免费筛查服务。为鼓励HIV高危人群主动接受筛查，从12月1日起，金域医学联合吉利德科学，为部分市/县区疾控、医疗机构艾滋病免费筛查活动提供支持。据悉，金域医学已有3个省级医学实验室获得确证实验室资格，可开展艾滋病及相关检测项目达100多项。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023120120210683c4aef6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023120120210683c4aef6&s=b","is_publish_highlight":false},{"id":"2388050684","title":"“抗癌神药”也致癌？6款CAR-T产品在美遭调查，影响有多大？","url":"https://stock-news.laohu8.com/highlight/detail?id=2388050684","media":"澎湃新闻","top":-1,"share":"https://www.laohu8.com/m/news/2388050684?lang=zh_cn&edition=full","pubTime":"2023-12-01 07:58","pubTimestamp":1701388718,"startTime":"0","endTime":"0","summary":"“抗癌神药”CAR-T疗法因安全性问题遭遇监管机构的调查。此次FDA的调查则将CAR-T疗法的安全性摆在了大众和行业面前。药明巨诺的瑞基奥仑赛注射液是国内获批的第二款CAR-T产品。FDA的调查公告宣布后的29日，科济药业大跌23.29%。截至目前，科济药业在研CAR-T产品，临床试验治疗患者总数超过500例，其中靶向BCMA CAR-T产品250余例，未观察到T细胞肿瘤案例。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202312010755088309ea8b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202312010755088309ea8b&s=b","is_publish_highlight":false},{"id":"2387423049","title":"吉利德科学上涨1.24%，报76.16美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2387423049","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2387423049?lang=zh_cn&edition=full","pubTime":"2023-11-30 23:47","pubTimestamp":1701359268,"startTime":"0","endTime":"0","summary":"11月30日，吉利德科学(GILD)盘中上涨1.24%，截至23:47，报76.16美元/股，成交6755.3万美元。财务数据显示，截至2023年09月30日，吉利德科学收入总额200.02亿美元，同比增长0.55%；归母净利润42.36亿美元，同比增长43.5%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2023/11/30234738631925.shtml","is_publish_highlight":false},{"id":"2387271891","title":"更新 4-美国 FDA 调查 CAR-T 癌症疗法的安全风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2387271891","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2387271891?lang=zh_cn&edition=full","pubTime":"2023-11-29 07:19","pubTimestamp":1701213550,"startTime":"0","endTime":"0","summary":" Pratik Jain    路透11月28日 - 美国食品和药物管理局 周二表示，它正在调查吉利德科学  、强生  、诺华  等公司生产的癌症疗法因严重的安全问题而导致的住院和死亡风险。自2017年以来，美国食品和药物管理局已批准了六种CAR-T细胞疗法，全部用于治疗血癌，包括淋巴瘤和某些形式的白血病。如果无意中收集了癌前细胞，并将其用于 CAR-T 治疗，可能会导致继发性癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false},{"id":"2387527140","title":"更新版 1-美国 FDA 调查 CAR-T 疗法的安全风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2387527140","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2387527140?lang=zh_cn&edition=full","pubTime":"2023-11-29 01:43","pubTimestamp":1701193437,"startTime":"0","endTime":"0","summary":"    路透11月28日 - 美国食品和药物管理局周二表示，在收到患者不良事件报告后，它正在调查吉利德  和强生  等公司生产的CAR-T疗法的安全风险。美国卫生监管机构正在调查已发现的T细胞恶性肿瘤风险，包括住院和死亡等严重后果，并正在评估采取监管行动的必要性。美国食品和药物管理局的调查还涉及目前已获批准的此类癌症疗法，包括百时美施贵宝公司  和诺华公司  的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false},{"id":"2385667017","title":"吉利德科学上涨1.22%，报75.6美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2385667017","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2385667017?lang=zh_cn&edition=full","pubTime":"2023-11-23 04:21","pubTimestamp":1700684488,"startTime":"0","endTime":"0","summary":"11月23日，吉利德科学(GILD)盘中上涨1.22%，截至04:21，报75.6美元/股，成交1.94亿美元。财务数据显示，截至2023年09月30日，吉利德科学收入总额200.02亿美元，同比增长0.55%；归母净利润42.36亿美元，同比增长43.5%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2023/11/23042138533221.shtml","is_publish_highlight":false},{"id":"2385578182","title":"吉利德科学下跌1.22%，报75.07美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2385578182","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2385578182?lang=zh_cn&edition=full","pubTime":"2023-11-21 23:03","pubTimestamp":1700579020,"startTime":"0","endTime":"0","summary":"11月21日，吉利德科学(GILD)盘中下跌1.22%，截至23:03，报75.07美元/股，成交4611.76万美元。财务数据显示，截至2023年09月30日，吉利德科学收入总额200.02亿美元，同比增长0.55%；归母净利润42.36亿美元，同比增长43.5%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2023/11/21230338515279.shtml","is_publish_highlight":false},{"id":"2384736269","title":"吉利德科学上涨1.21%，报75.42美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2384736269","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2384736269?lang=zh_cn&edition=full","pubTime":"2023-11-18 02:39","pubTimestamp":1700246365,"startTime":"0","endTime":"0","summary":"11月18日，吉利德科学(GILD)盘中上涨1.21%，截至02:39，报75.42美元/股，成交2.06亿美元。财务数据显示，截至2023年09月30日，吉利德科学收入总额200.02亿美元，同比增长0.55%；归母净利润42.36亿美元，同比增长43.5%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2023/11/18023938469792.shtml","is_publish_highlight":false},{"id":"2383822843","title":"吉利德科学上涨1.29%，报76.01美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2383822843","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2383822843?lang=zh_cn&edition=full","pubTime":"2023-11-16 22:32","pubTimestamp":1700145144,"startTime":"0","endTime":"0","summary":"11月16日，吉利德科学(GILD)开盘上涨1.29%，截至22:32，报76.01美元/股，成交68.63万美元。财务数据显示，截至2023年09月30日，吉利德科学收入总额200.02亿美元，同比增长0.55%；归母净利润42.36亿美元，同比增长43.5%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2023/11/16223238451491.shtml","is_publish_highlight":false},{"id":"2383234717","title":"吉利德科学2023财年第三财季实现净利润21.80亿美元，同比增加21.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2383234717","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2383234717?lang=zh_cn&edition=full","pubTime":"2023-11-13 00:23","pubTimestamp":1699806222,"startTime":"0","endTime":"0","summary":"9月30日，吉利德科学公布财报，公告显示公司2023财年第三财季净利润为21.80亿美元，同比增加21.86%；其中营业收入为70.35亿美元，同比增加0.59%，每股基本收益为1.75美元。从资产负债表来看，吉利德科学总负债401.30亿美元，其中短期债务17.93亿美元，资产负债比为1.56，流动比率为1.34。机构评级：截至2023年9月30日，当前有25家机构对吉利德科学目标价做出预测，其中目标均价为89.90美元，其中最低目标价为71.00美元，最高目标价为116.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231113002350840bed4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231113002350840bed4a&s=b","is_publish_highlight":false},{"id":"2382425405","title":"【直击进博会】亲历进博“溢出效应” 吉利德二次参展扩大在华朋友圈","url":"https://stock-news.laohu8.com/highlight/detail?id=2382425405","media":"新华财经","top":-1,"share":"https://www.laohu8.com/m/news/2382425405?lang=zh_cn&edition=full","pubTime":"2023-11-09 10:29","pubTimestamp":1699496953,"startTime":"0","endTime":"0","summary":"从去年首次参展的“头回客”到今年再赴进博之约的“回头客”，吉利德科学亲历展出药物的快速上市，见证了进博会带来的溢出效应。吉利德科学表示，期待借助“进博磁力”，进一步扩大在华“朋友圈”。目前，已有十一款创新药物在中国获批，其中八个药物已被列入国家医保目录。今年进博会，吉利德中国全面呈现了其在HIV防治、病毒性肝炎、肿瘤和抗真菌领域的“明星”创新药物。金方千表示，中国是吉利德全球三大重要战略市场之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023110910292083fc8abe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023110910292083fc8abe&s=b","is_publish_highlight":false},{"id":"2381193472","title":"吉利德科学：三季度瑞德西韦销售额同比下降31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2381193472","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2381193472?lang=zh_cn&edition=full","pubTime":"2023-11-08 17:32","pubTimestamp":1699435924,"startTime":"0","endTime":"0","summary":"11月8日，吉利德科学官微发布2023年第三季度财务报告。产品销售额（除瑞德西韦外）同比增长5%，达64亿美元；瑞德西韦销售额为6.36亿美元，同比下降31%。其中，比克恩丙诺片销售额同比增长12%，达31亿美元；肿瘤领域产品销售额同比增长33%，达7.69亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023110817320583030b24&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023110817320583030b24&s=b","is_publish_highlight":false},{"id":"2381494736","title":"吉利德：借助博鳌特许药械进口先行先试政策，推动中国患者国际“零时差”用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2381494736","media":"金融界网站","top":-1,"share":"https://www.laohu8.com/m/news/2381494736?lang=zh_cn&edition=full","pubTime":"2023-11-07 22:55","pubTimestamp":1699368948,"startTime":"0","endTime":"0","summary":"转自：金融界本文源自:金融界AI电报在第六届中国国际进口博览会上，吉利德与海南乐城管理局及四川大学华西乐城医院签订战略合作，将借助博鳌特许药械进口先行先试的政策推动中国患者实现与国际“零时差”用药。同日，吉利德宣布与北京市希思科临床肿瘤学研究基金会建立“希思科-吉利德肿瘤研究基金”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023110722555082565cb1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023110722555082565cb1&s=b","is_publish_highlight":false},{"id":"2381141202","title":"“头回客”再赴进博之约 共创健康中国美好未来","url":"https://stock-news.laohu8.com/highlight/detail?id=2381141202","media":"科技日报","top":-1,"share":"https://www.laohu8.com/m/news/2381141202?lang=zh_cn&edition=full","pubTime":"2023-11-06 11:49","pubTimestamp":1699242543,"startTime":"0","endTime":"0","summary":"参加了本届进博会开幕式的吉利德科学全球副总裁兼中国区总经理金方千表示，“今年，从进博‘头回客’到‘回头客’，我们将展台面积扩大五倍，全面展示公司在病毒学、肿瘤学、真菌学等疾病领域的创新产品，呈现公司全球研发布局、本土研发进展，为实现‘健康中国’的宏伟目标贡献吉利德科学的智慧和力量。”这两款药物去年在进博会首展，今年已在中国成功上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231106121445830247ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231106121445830247ef&s=b","is_publish_highlight":false},{"id":"2380137411","title":"中国机会｜吉利德全球副总裁：进博会助力创新药物中国上市进程","url":"https://stock-news.laohu8.com/highlight/detail?id=2380137411","media":"澎湃新闻","top":-1,"share":"https://www.laohu8.com/m/news/2380137411?lang=zh_cn&edition=full","pubTime":"2023-11-04 20:12","pubTimestamp":1699099952,"startTime":"0","endTime":"0","summary":"吉利德科学期待通过进博会的平台有更多的“进博宝宝”，助力创新产品能够更快上市，惠及更多的中国患者。目前，该药物的片剂和注射液也已在中国提交了上市申请。值得关注的是，吉利德科学还将于此次进博会全面展示其在全球及中国的研发布局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231104201252824a1957&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231104201252824a1957&s=b","is_publish_highlight":false},{"id":"2378404786","title":"进博故事·展品会说话丨进博会助力小药片实现“健康大梦想”","url":"https://stock-news.laohu8.com/highlight/detail?id=2378404786","media":"东方网","top":-1,"share":"https://www.laohu8.com/m/news/2378404786?lang=zh_cn&edition=full","pubTime":"2023-10-25 22:28","pubTimestamp":1698244080,"startTime":"0","endTime":"0","summary":"吉利德第五届进博会展台“进博宝宝”加速可及在医疗器械及医药保健展区，展商们习惯于把通过进博会实现“展品变商品”、加速推进可及的这类创新药物亲切地 称 为“进博宝宝”。“进博会为推进创新药物上市的整体进程提供了重要的助力。”接下来，吉利德将续深耕中国市场，助力更多承载着本土创新力量的小药片乘“进博东风”走向全球市场，服务更多患者，实现“健康大梦想”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102522410182235c77&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102522410182235c77&s=b","is_publish_highlight":false}],"profile":{"websiteUrl":"http://www.gilead.com","stockEarnings":[{"period":"1week","weight":0.0176},{"period":"1month","weight":0.0144},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.0115},{"period":"1year","weight":-0.1168},{"period":"ytd","weight":-0.0796}],"compareEarnings":[{"period":"1week","weight":0.0024},{"period":"1month","weight":0.0525},{"period":"3month","weight":0.033},{"period":"6month","weight":0.0705},{"period":"1year","weight":0.1614},{"period":"ytd","weight":0.2034}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"吉利德科学公司于1987年6月22日在特拉华州成立，是一家以研究为基础的生物制药公司，致力于发现，开发和商业化未满足医疗需求的创新药物。该公司的主要重点领域包括病毒性疾病，炎性和纤维化疾病以及肿瘤学。","yearOnYearQuotes":[{"month":1,"riseRate":0.580645,"avgChangeRate":0.043622},{"month":2,"riseRate":0.40625,"avgChangeRate":0.004571},{"month":3,"riseRate":0.53125,"avgChangeRate":-0.010195},{"month":4,"riseRate":0.5625,"avgChangeRate":0.017693},{"month":5,"riseRate":0.5625,"avgChangeRate":0.021083},{"month":6,"riseRate":0.625,"avgChangeRate":0.024943},{"month":7,"riseRate":0.53125,"avgChangeRate":0.013302},{"month":8,"riseRate":0.53125,"avgChangeRate":0.033833},{"month":9,"riseRate":0.5625,"avgChangeRate":0.031735},{"month":10,"riseRate":0.5,"avgChangeRate":-0.00096},{"month":11,"riseRate":0.625,"avgChangeRate":0.039318},{"month":12,"riseRate":0.40625,"avgChangeRate":0.010775}],"exchange":"NASDAQ","name":"吉利德科学","nameEN":"Gilead Sciences"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.19.1","shortVersion":"4.19.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"吉利德科学,GILD,吉利德科学股票,吉利德科学股票老虎,吉利德科学股票老虎国际,吉利德科学行情,吉利德科学股票行情,吉利德科学股价,吉利德科学股市,吉利德科学股票价格,吉利德科学股票交易,吉利德科学股票购买,吉利德科学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}